The drug’s high cost is the source of a growing debate among healthcare professionals, drug makers, and patients. (1)

New hepatitis C (HCV) drugs are too expensive for most patients. For example, “a standard course of Sovaldi costs $84,000, or $1,000 a day. And many insurers would not approve it for any but the sickest of patients.” (1)

Additionally, barriers have been put up by private insurance companies and state Medicaid programs “aimed at controlling costs (which have) made it hard for patients to get the drug, with many left to worsen as they sought charity or appealed their cases.” (1)

Dr. Paul J. Thuluvath said “Here we had this disease we couldn’t cure, and this drug is developed and it’s almost like a miracle. I was so upset it was so expensive.” (1) Dr. Thuluvath is a professor at the University of Maryland School of Medicine and author of a forthcoming hepatitis guide.

An article in Forbes magazine noted that these high costs “are hitting Medicaid health insurance programs for poor Americans particularly hard because the population of patients in need of Hepatitis C treatments tends to have low incomes and wouldn’t be able to afford the drug otherwise. Medicaid is funded by state and federal tax dollars and administered by state governments.” (2)

The bottom line?

The new hepatitis drugs may work, but almost nobody can afford them.

References:

(1) Cohn, M. “Hepatitis C drug can cure, if patients can get it” Published July 18, 2015
baltimoresun.com

(2) Forbes.com – As Pricey Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles. Published October 10, 2014.
http://www.forbes.com/sites/brucejapsen/2014/10/10/as-hepatitis-pill-harvoni-joins-sovaldi-states-erect-medicaid-hurdles/